CRVS Corvus Pharmaceuticals Inc

Price (delayed)

$12.54

Market cap

$1.05B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.61

Enterprise value

$1.04B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 7

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead ...

Highlights
The debt has contracted by 33% YoY and by 13% from the previous quarter
Corvus Pharmaceuticals's equity has surged by 181% YoY but it has decreased by 6% QoQ
The quick ratio has soared by 80% YoY but it has contracted by 19% from the previous quarter
Corvus Pharmaceuticals's net income has decreased by 23% QoQ and by 20% YoY

Key stats

What are the main financial stats of CRVS

CRVS stock price

How has the Corvus Pharmaceuticals stock price performed over time
Intraday
-6.7%
1 week
2.53%
1 month
-13.28%
1 year
104.9%
YTD
62.86%
QTD
-16.06%

Financial performance

How have Corvus Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$56.96M
Net income
-$54.13M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 60% year-on-year and by 19% since the previous quarter
Corvus Pharmaceuticals's net income has decreased by 23% QoQ and by 20% YoY

Price vs fundamentals

How does CRVS's price correlate with its fundamentals

Growth

What is Corvus Pharmaceuticals's growth rate over time

Valuation

What is Corvus Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.68
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 17% QoQ but it has increased by 6% YoY
Corvus Pharmaceuticals's equity has surged by 181% YoY but it has decreased by 6% QoQ
The price to book (P/B) is 27% lower than the last 4 quarters average of 6.9 but 12% higher than the 5-year quarterly average of 4.5

Efficiency

How efficient is Corvus Pharmaceuticals business performance
Corvus Pharmaceuticals's return on invested capital has surged by 67% YoY and by 9% QoQ
The ROE has soared by 65% year-on-year and by 7% since the previous quarter
The company's return on assets rose by 49% YoY and by 6% QoQ

Dividends

What is CRVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRVS.

Financial health

How did Corvus Pharmaceuticals financials performed over time
The total assets has soared by 167% YoY but it has contracted by 5% from the previous quarter
CRVS's current ratio has soared by 81% YoY but it is down by 18% from the previous quarter
The debt is 100% less than the equity
Corvus Pharmaceuticals's equity has surged by 181% YoY but it has decreased by 6% QoQ
The debt to equity has dropped by 100% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.